Pfizer says its Omicron-containing boosters outperform current vaccine
Pfizer said Saturday that using new versions of its Covid-19 vaccine as boosters led to a superior antibody response against the Omicron variant compared to its current shot.
The results in some ways mirror those released by Moderna earlier this month. Data from both companies will be evaluated on Tuesday by a panel of experts convened by the Food and Drug Administration in the hopes of deciding what strains of the SARS-Cov-2 virus should be included in booster shots for the fall. Companies will need lead time to manufacture doses of new vaccines if it is decided they are needed.
Read Original Article: Pfizer says its Omicron-containing boosters outperform current vaccine »
